Document Detail

Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.
MedLine Citation:
PMID:  20464498     Owner:  NLM     Status:  MEDLINE    
Genetic mutations that severely diminish the activity of aspartoacylase (ASPA) result in the fatal brain dysmyelinating disorder, Canavan disease. There is no effective treatment. ASPA produces free acetate from the concentrated brain metabolite, N-acetylaspartate (NAA). Because acetyl coenzyme A is a key building block for lipid synthesis, we postulated that the inability to catabolize NAA leads to a brain acetate deficiency during a critical period of CNS development, impairing myelination and possibly other aspects of brain development. We tested the hypothesis that acetate supplementation during postnatal myelination would ameliorate the severe phenotype associated with ASPA deficiency using the tremor rat model of Canavan disease. Glyceryltriacetate (GTA) was administered orally to tremor rats starting 7 days after birth, and was continued in food and water after weaning. Motor function, myelin lipids, and brain vacuolation were analyzed in GTA-treated and untreated tremor rats. Significant improvements were observed in motor performance and myelin galactocerebroside content in tremor rats treated with GTA. Further, brain vacuolation was modestly reduced, and these reductions were positively correlated with improved motor performance. We also examined the expression of the acetyl coenzyme A synthesizing enzyme acetyl coenzyme A synthase 1 and found upregulation of expression in tremor rats, with a return to near normal expression levels in GTA-treated tremor rats. These results confirm the critical role played by NAA-derived acetate in brain myelination and development, and demonstrate the potential usefulness of acetate therapy for the treatment of Canavan disease.
Peethambaran Arun; Chikkathur N Madhavarao; John R Moffett; Kristen Hamilton; Neil E Grunberg; Prasanth S Ariyannur; William A Gahl; Yair Anikster; Steven Mog; William C Hallows; John M Denu; Aryan M A Namboodiri
Related Documents :
15878668 - New selective acetylcholinesterase inhibitors designed from natural piperidine alkaloids.
11468328 - Limbic encephalitis associated with recurrent thymoma: a postmortem study.
1847198 - Interactions of sigma and phencyclidine receptor ligands with the norepinephrine uptake...
7422058 - Antigenic properties of the loosely bound subnuclear fraction of rat brain.
2335008 - Carcinogenicity of naturally occurring 1-hydroxyanthraquinone in rats: induction of lar...
8968058 - Inhibition of rat liver cytochrome p450 isozymes by isothiocyanates and their conjugate...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-05-13
Journal Detail:
Title:  Journal of inherited metabolic disease     Volume:  33     ISSN:  1573-2665     ISO Abbreviation:  J. Inherit. Metab. Dis.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-27     Completed Date:  2010-09-28     Revised Date:  2014-09-16    
Medline Journal Info:
Nlm Unique ID:  7910918     Medline TA:  J Inherit Metab Dis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  195-210     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetates / therapeutic use*
Aspartic Acid / analogs & derivatives*,  metabolism,  therapeutic use
Brain / metabolism
Canavan Disease / therapy*
Disease Models, Animal
Lipids / chemistry
Myelin Sheath / chemistry
Treatment Outcome
Grant Support
Reg. No./Substance:
0/Acetates; 0/Lipids; 30KYC7MIAI/Aspartic Acid; 997-55-7/N-acetylaspartate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prosta...
Next Document:  Multiphysics simulation of a microfluidic perfusion chamber for brain slice physiology.